Cancer Therapy News and Research

RSS

EAUN launches new online course on bone health and urological cancer

The European Association of Urology Nurses launched a new online course for urology nurses and affiliated professionals "Bone health and urological cancer". This course tackles a highly pressing issue of maintaining and promoting bone health in cancer patients.

29 Nov 2013

NHPA report compares performance of Queensland hospitals on cancer surgeries

Cancer Council Queensland has welcomed the first release of cancer surgery waiting times from the National Hospital Performance Authority.

28 Nov 2013

Diagnosing colonic polyps: an interview with Dr. Haili Wang, Metabolomic Technologies Inc. (MTI)

Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.

28 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Biochemist receives grant to identify pathway to regulate DNA damage repair in cancer cells

Chemotherapy and radiation therapy are often used to kill cancer cells by causing irreparable DNA damage. However, some cancer patients resist chemotherapy and radiation due to a highly active DNA damage repair system.

26 Nov 2013

Researcher receives $225,000 grant to study epigenetic changes associated with chemotherapy

Western University cancer researcher Shun-Cheng (Shawn) Li, PhD, has been awarded a China-Canada Joint Health Research Initiative grant from the Canadian Institutes of Health Research (CIHR).

26 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Researchers identify new form of treatment for brain tumor

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.

26 Nov 2013

Nutranomics joins Genesar Nutraceuticals to acquire worldwide licence for GenEpic

Nutranomics, Inc. is pleased to announce that the Company has completed a Licence Agreement with Genesar Nutraceuticals, LLC to acquire the worldwide exclusive marketing and distributing rights to GenEpic, a natural therapeutic treatment formula currently the subject of an IRB reviewed phase II human clinical study on prostate cancer treatment and recovery.

25 Nov 2013

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

...

22 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

20 Nov 2013

UC San Diego study suggests racial inequality leads to higher mortality in cancer patients

Researchers at the University of California, San Diego School of Medicine say metastatic colorectal cancer patients of African-American descent are less likely to be seen by cancer specialists or receive cancer treatments. This difference in treatment explains a large part of the 15 percent higher mortality experienced by African-American patients than non-Hispanic white patients.

20 Nov 2013

Study: Blood cell growth factor improves effects of exercise in patients with peripheral artery disease

A blood cell growth factor can boost the effects of exercise in improving mobility for patients with peripheral artery disease, a clinical study has shown.

19 Nov 2013

Study confirms therapeutic potential of inhibiting Aurora-A in cancer treatment

Aurora-A is a protein involved in the cell division process that is highly expressed or synthesised in a large number of human cancers, especially in those associated with a bad prognosis. Several pharmaceutical companies have recently developed these protein inhibitors, although the therapeutic and physiological effects that blocking Aurora-A might have on adult tissues are still unknown.

19 Nov 2013

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

Extract taken from an Asian vegetable may have therapeutic qualities to treat head and neck cancer, a Saint Louis University researcher has found.

19 Nov 2013

Young adults who had childhood cancer more likely to be frail than their peers

Young adults who survived childhood cancer are more likely than their peers to be frail, according to a St. Jude Children's Research Hospital study, which reported the condition is more common among female survivors than women decades older. The research appears in the November 18 online edition of the Journal of Clinical Oncology.

18 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

Scientists reveal surprising role for HDAC1 proteins in development of skin tumors

Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) - a member of a family of chromatin modifying proteins - in the development of skin tumors.

18 Nov 2013

Cancer Therapy News and Research

EAUN launches new online course on bone health and urological cancer

NHPA report compares performance of Queensland hospitals on cancer surgeries

Diagnosing colonic polyps: an interview with Dr. Haili Wang, Metabolomic Technologies Inc. (MTI)

UMass Medical School licenses "anti-gal" technology to Agalimmune

Biochemist receives grant to identify pathway to regulate DNA damage repair in cancer cells

Researcher receives $225,000 grant to study epigenetic changes associated with chemotherapy

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Researchers identify new form of treatment for brain tumor

Nutranomics joins Genesar Nutraceuticals to acquire worldwide licence for GenEpic

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

UC San Diego study suggests racial inequality leads to higher mortality in cancer patients

Study: Blood cell growth factor improves effects of exercise in patients with peripheral artery disease

Study confirms therapeutic potential of inhibiting Aurora-A in cancer treatment

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

Young adults who had childhood cancer more likely to be frail than their peers

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Scientists reveal surprising role for HDAC1 proteins in development of skin tumors

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News